Trial Profile
A prospective study of 123I-MIBG SPECT in patients with multiple system atrophy and parkinson's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2016
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Atrophy; Parkinson's disease
- Focus Diagnostic use
- 26 Sep 2016 New trial record